[go: up one dir, main page]

NO20074634L - Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer - Google Patents

Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer

Info

Publication number
NO20074634L
NO20074634L NO20074634A NO20074634A NO20074634L NO 20074634 L NO20074634 L NO 20074634L NO 20074634 A NO20074634 A NO 20074634A NO 20074634 A NO20074634 A NO 20074634A NO 20074634 L NO20074634 L NO 20074634L
Authority
NO
Norway
Prior art keywords
pdk1
chk1
substituted heterocycles
pak inhibitors
inhibitory activity
Prior art date
Application number
NO20074634A
Other languages
English (en)
Norwegian (no)
Inventor
Nicola Murdoch Heron
Paul Dermot Lyne
Dorin Toader
Dingwei Yu
Yan Yu
James Janetka
Stephanos Ioannidis
Kevin Daly
Alexander Hird
Jamie Scott
Melissa Vasbinder
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36586532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074634(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20074634L publication Critical patent/NO20074634L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20074634A 2005-04-06 2007-09-12 Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer NO20074634L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66877905P 2005-04-06 2005-04-06
US73886605P 2005-11-21 2005-11-21
PCT/GB2006/001242 WO2006106326A1 (en) 2005-04-06 2006-04-05 Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors

Publications (1)

Publication Number Publication Date
NO20074634L true NO20074634L (no) 2007-10-31

Family

ID=36586532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074634A NO20074634L (no) 2005-04-06 2007-09-12 Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer

Country Status (15)

Country Link
US (1) US20090275570A1 (es)
EP (1) EP1869052A1 (es)
JP (1) JP2008534664A (es)
KR (1) KR20080009200A (es)
AR (1) AR053352A1 (es)
AU (1) AU2006232620A1 (es)
BR (1) BRPI0608659A2 (es)
CA (1) CA2601983A1 (es)
IL (1) IL186112A0 (es)
MX (1) MX2007012448A (es)
NO (1) NO20074634L (es)
RU (1) RU2007140734A (es)
TW (1) TW200714604A (es)
UY (1) UY29458A1 (es)
WO (1) WO2006106326A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
RU2425834C2 (ru) * 2005-11-08 2011-08-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ТИАЗОЛО[4,5-c]ПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ mGluR5
JP2009516702A (ja) * 2005-11-18 2009-04-23 スミスクライン・ビーチャム・コーポレイション 化合物
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US7994321B2 (en) 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
ATE531720T1 (de) * 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
EP2069359B1 (en) * 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
WO2008060448A2 (en) * 2006-11-10 2008-05-22 Massachusetts Institute Of Technology Small molecule pak inhibitors
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US20100226917A1 (en) * 2007-04-27 2010-09-09 Astrazeneca Ab Methods for the treatment of hematologic malignancies
JP5464709B2 (ja) 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
CA2687912C (en) 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2687754C (en) 2007-06-08 2015-12-08 Janssen Pharmaceutica N.V. Piperidine, piperazine derivatives for use as dgat inhibitors
JP5489296B2 (ja) * 2007-12-13 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US7998688B2 (en) 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
EP2177510A1 (en) * 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
PT2406253E (pt) 2009-03-11 2013-09-11 Pfizer Derivados de benzofuranilo utilizados como inibidores de glucocinase
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
BR112012006062A2 (pt) * 2009-09-18 2015-09-08 Zhanggui Wu novos compostos e respectivo uso terapêutico para inibição de proteína quinase
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
CN103298461A (zh) 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法
DE102011008352A1 (de) 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
EP2702063A1 (en) 2011-04-29 2014-03-05 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
MX2014010953A (es) 2012-03-16 2014-10-13 Hoffmann La Roche Metodos para tratamiento de melanoma con inhibidores pak1.
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
WO2014085607A1 (en) 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
PL2938598T3 (pl) 2012-12-31 2017-05-31 Cadila Healthcare Limited Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
KR102273997B1 (ko) * 2013-06-26 2021-07-08 애브비 인코포레이티드 Btk 억제제로서 1급 카복스아미드
MX367618B (es) 2013-07-03 2019-08-28 Karyopharm Therapeutics Inc Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
WO2015042414A1 (en) * 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
EP2865757A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
KR20230026515A (ko) * 2014-09-10 2023-02-24 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
JP6517928B2 (ja) 2014-10-24 2019-05-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤として有用なインドールカルボキシアミド
US20170369470A1 (en) * 2014-12-16 2017-12-28 Karyopharm Therapeutics Inc. Cyclic Compounds and Uses Thereof
CR20170420A (es) 2015-03-13 2017-10-03 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
MX2018001979A (es) 2015-08-18 2019-04-25 Karyopharm Therapeutics Inc (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2020186283A1 (en) * 2019-03-18 2020-09-24 The Council Of The Queensland Institute Of Medical Research Cardiomyocyte proliferation
CN115038440A (zh) * 2020-01-07 2022-09-09 上海华禹生物科技有限公司 使用chk抑制剂的癌症联合疗法
JP2024503280A (ja) * 2020-12-29 2024-01-25 レボリューション メディシンズ インコーポレイテッド Ｓｏｓ１阻害剤及びその使用
CN113861215B (zh) * 2021-09-18 2022-05-17 济宁医学院附属医院 一种选择性铜离子螯合剂、其制备方法及其在结直肠癌中的应用
CN113816970B (zh) * 2021-09-18 2022-08-09 济宁医学院附属医院 一种选择性铜离子螯合剂、其制备方法及其在肺纤维化中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050037585A (ko) * 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
US20050148643A1 (en) * 2003-08-19 2005-07-07 Agouron Pharmaceuticals, Inc. Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme

Also Published As

Publication number Publication date
MX2007012448A (es) 2007-10-19
TW200714604A (en) 2007-04-16
RU2007140734A (ru) 2009-05-20
JP2008534664A (ja) 2008-08-28
AU2006232620A1 (en) 2006-10-12
EP1869052A1 (en) 2007-12-26
UY29458A1 (es) 2006-11-30
BRPI0608659A2 (pt) 2010-11-30
WO2006106326A1 (en) 2006-10-12
KR20080009200A (ko) 2008-01-25
US20090275570A1 (en) 2009-11-05
WO2006106326A8 (en) 2007-11-29
AR053352A1 (es) 2007-05-02
CA2601983A1 (en) 2006-10-12
IL186112A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
NO20081454L (no) Met-kinaseinhibitorer
NO20090783L (no) Pyrimidonforbindelser som inhibitorer av GSK-3
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20071005L (no) Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20061743L (no) Kinazolinderivater
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20084712L (no) Nye farmasoytiske forbindelser
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
NO20071593L (no) Pyrimidinderivater
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
NO20061327L (no) Kinazolinderivater
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application